Skip to Main Content

Yale Psychedelic Science Group

With the recent re-emergence of psychedelic research demonstrating therapeutic efficacy for a variety of psychiatric and medical conditions, a small group of residents, fellows, and faculty at Yale that initially met informally to discuss current research recognized the need for a more structured educational initiative to illuminate this important and rapidly growing area of science. The Yale Psychedelic Science Group (YPSG) was established in January 2016 as an interest group within the Yale Department of Psychiatry to discuss issues at the intersection of psychedelic substances and psychiatry.

Although the YPSG hopes to enlarge the scope of its discussion and activities, its initial focus will be on contemporary clinical research and the mechanisms of action of psychedelic treatments. Therefore, the YPSG has organized a forum where clinicians and scholars from across Yale can learn about and discuss recent studies in an academically rigorous manner. At our monthly meetings, research scientists from outside institutions who are actively engaged in clinical studies with classical psychedelic compounds present their findings. The primary objectives of this forum are to promote a critical examination of the presented work and to encourage the sharing of interdisciplinary perspectives during the ensuing discussion period.

Members of the YPSG organizing committee can be reached at yalepsg@gmail.com. You may subscribe, unsubscribe or edit your subscription to the YPSG email listserv by visiting https://mailman.yale.edu/mailman/listinfo/yalepsych

Yale Psychedelic Science Group Leadership:
Resident Leader – William Prueitt
Faculty Advisor – Ben Kelmendi

Upcoming Events

To be announced soon. Please sign up for our mailing list to receive up to date information about future speakers.

Seminars

2022

February 3, 2022 - Raquel Bennett, PsyD is a psychologist and ketamine specialist from Berkeley, California. She primarily works with people who are living with severe depression, bipolar disorder, and/or suicidal ideation. Dr. Bennett is fascinated by the antidepressant and anti-obsessional properties of ketamine, and has been studying them since 2002. She also has a long-standing interest in the psychedelic and mystical properties of ketamine, and the potential for this medicine to be used for spiritual exploration. Dr. Bennett is the founder of KRIYA Institute and KRIYA Conference, which are both devoted to the use of ketamine in psychiatry and psychotherapy. She has given hundreds of lectures and trained thousands of clinicians worldwide on the safe and legal use of ketamine in clinical practice. You can learn more about her work at: www.kriyainstitute.com/

Title - Expanding Our Understanding of Ketamine in Psychiatry and Psychotherapy

May 18, 2022 - David Casimir is a patent attorney with Casimir Jones, an intellectual property law firm that specializes in biological and chemical technologies. David has a bachelor’s degree in cellular and molecular biology from the University of Michigan, a master’s degree and Ph.D. in biochemistry from the University of Wisconsin, and a law degree from Stanford University. In addition to his legal practice, David teaches at the University of Wisconsin law school and has guest taught courses at the University of Wisconsin business school and the University of Michigan school of pharmacy. David is a board member of the EHE Foundation (a rare cancer organization supporting research and patient services) and the Isthmus Project (a subsidiary of UW Health focused on innovation) and is an advisory board member for the University of Wisconsin Law School Law and Entrepreneurship Clinic. David is one of the co-founders of Porta Sophia, a psychedelic prior art library.

Title - Protecting the Integrity of the Psychedelic Patent Landscape